Abstract
This review summarizes the pharmacology, safety and clinical efficacy of nomegestrol acetate, based on the available published literature, and assesses the pharmacological characteristics that underlie a role in different gynaecological disorders and hormone replacement therapy (HRT), and a potential role in combination estrogen/progestogen oral contraception. Nomegestrol acetate is a potent, orally active progestogen with a favourable tolerability profile and neutral metabolic characteristics. Unlike the majority of older progestogens, which were 19-nortestosterone derivatives synthesized primarily for their antigonadotropic activity as a component of hormonal contraception in combination with an estrogen, nomegestrol acetate is a 19-norprogesterone derivative designed to bind specifically to the progesterone receptor, and is relatively lacking in affinity for other steroid receptors. Nomegestrol acetate exerts strong antiestrogenic effects at the level of the endometrium and has potent antigonadotropic activity, but without any residual androgenic or glucocorticoid properties. At a dosage of 1.25 mg/day, nomegestrol acetate inhibits ovulation while permitting follicle growth, whereas at dosages of 2.5 or 5 mg/day, both ovulation and follicle development are suppressed. The antigonadotropic action of nomegestrol acetate is mediated, like other progestins, at the hypothalamic and pituitary level. Moreover, nomegestrol acetate has partial antiandrogenic activity. Absorption of nomegestrol acetate is rapid after oral administration, reaching a peak serum concentration within 4 hours, with a terminal half-life of approximately 50 hours.
Nomegestrol acetate has been used successfully for the treatment of some gynaecological disorders (menstrual disturbances, dysmenorrhoea, premenstrual syndrome) and as a component of HRT in combination with estradiol for the relief of menopausal symptoms; it has been approved in Europe as monotherapy for the treatment of the menopausal syndrome, uterine diseases and menorrhagia, and in combination with an estrogen for the treatment of menopausal symptoms. In vitro data suggest that nomegestrol acetate preserves the beneficial haemostatic effects of estrogen; furthermore, nomegestrol acetate has a neutral or beneficial effect on lipid profiles, and does not adversely affect glucose metabolism or bodyweight. Nomegestrol acetate has shown a lack of profilerative activity in normal and cancerous breast tissue, and does not have a deleterious effect on bone remodelling.
These potent antigonadotropic properties, and other beneficial metabolic and pharmacological characteristics, suggest that nomegestrol acetate can be an effective progestogen for use in combination with an estrogen in oral estrogen/progestogen contraceptive treatment and in HRT, while it also provides some non-contraceptive benefits for women’s health.
Similar content being viewed by others
References
Kuhl H. Comparative pharmacology of newer progestogens. Drugs 1996 Feb; 51(2): 188–215
Sitruk-Ware R. New progestogens: a review of their effects in perimenopausal and postmenopausal women. Drugs Aging 2004; 21(13): 865–83
Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas 2003 Dec 10; 46 Suppl. 1: S7–16
Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2004 Apr 15; 47(4): 277–83
Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update 2006 Mar–Apr; 12(2): 169–78
Pasqualini JR. Progestins and breast cancer. Gynecol Endocrinol 2007 Oct; 23 Suppl. 1: 32–41
Kumar N, Koide SS, Tsong Y, et al. Nestorone: a progestin with a unique pharmacological profile. Steroids 2000 Oct–Nov; 65(10–11): 629–36
Paris J, Thevenot R, Bonnet P, et al. The pharmacological profile of TX 066 (17 alpha-acetoxy-6-methyl-19-nor-4,6-pregna-diene-3,20-dione), a new oral progestative. Arzneimittelforschung 1983; 33(5): 710–5
Duc I, Botella J, Bonnet P, et al. Antiandrogenic properties of nomegestrol acetate. Arzneimittelforschung 1995 Jan; 45(1): 70–4
Bullock LP, Bardin CW. Androgenic, synandrogenic, and antiandrogenic actions of progestins. Ann N Y Acad Sci 1977 Mar 11; 286: 321–30
Bazin B, Thevenot R, Bursaux C, et al. Effect of nomegestrol acetate, a new 19-nor-progesterone derivative, on pituitary-ovarian function in women. Br J Obstet Gynaecol 1987 Dec; 94(12): 1199–204
Couzinet B, Young J, Kujas M, et al. The antigonadotropic activity of a 19-nor-progesterone derivative is exerted both at the hypothalamic and pituitary levels in women. J Clin Endocrinol Metab 1999 Nov; 84(11): 4191–6
Couzinet B, Young J, Brailly S, et al. The antigonadotropic activity of progestins (19-nortestosterone and 19-norpro-gesterone derivatives) is not mediated through the androgen receptor. J Clin Endocrinol Metab 1996 Dec; 81(12): 4218–23
Data on file, Theramex S.p.A., 2002
Ezan E, Benech H, Bucourt R, et al. Enzyme immunoassay for nomegestrol acetate in human plasma. J Steroid Biochem Mol Biol 1993 Oct; 46(4): 507–14
Dusterberg B, Humpel M, Speck U. Terminal half-lives in plasma and bioavailability of norethisterone, levonorgestrel, cyproterone acetate and gestodene in rats, beagles and rhesus monkeys. Contraception 1981 Dec; 24(6): 673–83
Cohen A. Multicenter study of the clinical use of nomegestrol acetate in outpatients. Contracept Fertil Sex (Paris) 1994; 21: 417–27
Cohen A, Engelmann P, Erny R, et al. Lutenyl and menstrual disorders: a hospital study. Rev Fr Gynecol Obstet 1988 Nov; 83(11): 741–3
Persiani P, Radici E, Lombardi PA, et al. Use of nomegestrol acetate in the treatment of menstruation disorders: our experience in 56 cases. Minerva Ginecol 1997 Apr; 49(4): 181–5
Conard J, Basdevant A, Thomas JL, et al. Cardiovascular risk factors and combined estrogen-progestin replacement therapy: a placebo-controlled study with nomegestrol acetate and estradiol. Fertil Steril 1995 Nov; 64(5): 957–62
Fraser DI, Padwick ML, Whitehead MI, et al. The effects of the addition of nomegestrol acetate to post-menopausal oestrogen therapy. Maturitas 1989 Mar; 11(1): 21–34
De Leo V, la Marca A, Morgante G, et al. Comparison of two HRT regimens with bimonthly and monthly progestin administration in postmenopause. Maturitas 1999 Jan 4; 31(2): 171–7
Di Carlo C, Sammartino A, Di Spiezio Sardo A, et al. Bleeding patterns during continuous estradiol with different sequential progestogens therapy. Menopause 2005 Sep–Oct; 12(5): 520–5
Chretien FC, Dubois R. Effect of nomegestrol acetate on spinability, ferning and mesh dimension of midcycle cervical mucus. Contraception 1991 Jan; 43(1): 55–65
Coutinho EM. One year contraception with a single sub-dermal implant containing nomegestrol acetate (Uniplant). Contraception 1993 Jan; 47(1): 97–105
Devoto L, Kohen P, Barnhart K, et al. Hormonal profile, endometrial histology and ovarian ultrasound assessment during 1 year of nomegestrol acetate implant (Uniplant). Hum Reprod 1997 Apr; 12(4): 708–13
Basdevant A, Pelissier C, Conard J, et al. Effects of nomegestrol acetate (5 mg/d) on hormonal, metabolic and hemostatic parameters in premenopausal women. Contraception 1991 Dec; 44(6): 599–605
Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996 Oct 12; 348(9033): 977–80
Jick H, Derby LE, Myers MW, et al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996 Oct 12; 348(9033): 981–3
Perez Gutthann S, Garcia Rodriguez LA, Castellsague J, et al. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ 1997 Mar 15; 314(7083): 796–800
Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Oral contraceptives, hormone replacement therapy and thrombosis. Thromb Haemost 2001 Jul; 86(1): 112–23
Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, et al. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995 Dec 16; 346(8990): 1593–6
Jick H, Kaye JA, Vasilakis-Scaramozza C, et al. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ 2000 Nov 11; 321(7270): 1190–5
World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995 Dec 16; 346(8990): 1582–8
Zerr-Fouineau M, Chataigneau M, Blot C, et al. Progestins overcome inhibition of platelet aggregation by endothelial cells by down-regulating endothelial NO synthase via glucocorticoid receptors. FASEB J 2007 Jan; 21(1): 265–73
Zerr-Fouineau M, Jourdain M, Boesch C, et al. Certain progestins prevent the enhancing effect of 17s betas -estradiol on NO-mediated inhibition of platelet aggregation by endothelial cells. Arterioscler Thromb Vasc Biol 2009; 29(4): 586–93
Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003 Aug 9; 362(9382): 428–32
Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007 Feb 20; 115(7): 840–5
Canonico M, Oger E, Plu-Bureau G, et al. Response to letter regarding article, “Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study” [letter]. Circulation 2007; 116: e363
Post MS, Hendriks DF, Van Der Mooren MJ, et al. Oral oestradiol/trimegestone replacement reduces procarboxypeptidase U (TAFI): a randomized, placebo-controlled, 12-week study in early postmenopausal women. J Intern Med 2002 Mar; 251(3): 245–51
van Baal WM, Emeis JJ, van der Mooren MJ, et al. Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study. Thromb Haemost 2000 Jan; 83(1): 29–34
Archer DF. The effect of the duration of progestin use on the occurrence of endometrial cancer in postmenopausal women. Menopause 2001 Jul–Aug; 8(4): 245–51
Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995 Feb; 85(2): 304–13
Toni F, Lentini GM, Baldi S, et al. Endometrial histopathology and compliance of the treatment with nomegestrolo acetate versus micronized vaginal progesterone in the transdermal estrogen replacement therapy [abstract]. 2nd International Symposium on Women’s Health and Menopause; 1996 Dec 4–7; Florence
Williams JK, Honore EK, Washburn SA, et al. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol 1994 Dec; 24(7): 1757–61
Williams JK, Cline JM, Honore EK, et al. Coadministration of nomegestrol acetate does not diminish the beneficial effects of estradiol on coronary artery dilator responses in nonhuman primates (Macaca fascicularis). Am J Obstet Gynecol 1998 Nov; 179(5): 1288–94
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002 Jul 17; 288(3): 321–33
Chakhtoura Z, Canonico M, Gompel A, et al. Progestogenonly contraceptives and the risk of stroke: a meta-analysis. Stroke 2009; 40(4): 1059–62
Gerich JE. Type 2 diabetes mellitus is associated with multiple cardiometabolic risk factors. Clin Cornerstone 2007; 8(3): 53–68
The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995 Jan 18; 273(3): 199–208
Dorangeon P, Thomas JL, Gillery P, et al. Short term effects on lipids and lipoproteins of two progesterones used in postmenopausal replacement therapy. Eur J Clin Res 1992; 3: 187–93
Dorangeon P, Thomas JL, Choisy H, et al. Effects of nomegestrol acetate on carbohydrate metabolism. Diabete Metab 1993 Sep-Oct; 19(5): 441–5
Gol M, Akan P, Dogan E, et al. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels. Maturitas 2006 Feb 20; 53(3): 252–9
Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003 Aug 9; 362(9382): 419–27
Speroff L. The Million Women Study and breast cancer. Maturitas 2003 Sep 25; 46(1): 1–6
Shields-Botella J, Chetrite G, Meschi S, et al. Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells. J Steroid Biochem Mol Biol 2005 Jan; 93(1): 1–13
Chetrite G, Paris J, Botella J, et al. Effect of nomegestrol acetate on estrone-sulfatase and 17beta-hydroxysteroid dehydrogenase activities in human breast cancer cells. J Steroid Biochem Mol Biol 1996 Aug; 58(5–6): 525–31
Chetrite GS, Thomas JL, Shields-Botella J, et al. Control of sulfatase activity by nomegestrol acetate in normal and cancerous human breast tissues. Anticancer Res 2005 Jul–Aug; 25(4): 2827–30
Chetrite GS, Paris J, Shields-Botella J, et al. Effect of nomegestrol acetate on human estrogen sulfotransferase activity in the hormone-dependent MCF-7 and T-47D breast cancer cell lines. Anticancer Res 2003 Nov–Dec; 23(6C): 4651–5
Botella J, Duranti E, Duc I, et al. Inhibition by nomegestrol acetate and other synthetic progestins on proliferation and progesterone receptor content of T47-D human breast cancer cells. J Steroid Biochem Mol Biol 1994 Jul; 50(1–2): 41–7
Catherino WH, Jeng MH, Jordan VC. Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism. Br J Cancer 1993 May; 67(5): 945–52
Catherino WH, Jordan VC. Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activity. J Steroid Biochem Mol Biol 1995 Nov; 55(2): 239–46
Nguyen-Pascal ML, Thomas JL, Bergougnoux L, et al. Nomegestrol acetate may enhance the skeletal effects of estradiol on biochemical markers of bone turnover in menopausal women after a 12-week treatment period. Climacteric 2005 Jun; 8(2): 136–45
Cohen A, Denis C, Thomas JL. Treatment of perimenopausal women with 5 mg/d of nomegestrol acetate for 20 days of the cycle. Contracept Fertil Sex (Paris) 1992; 20(11): 1054–7
Medical News Today. Pivotal phase IIIa trials for Organon’s novel oral contraceptive, NOMAC/E2: complete recruitment [online]. Available from URL: http://www.medicalnewstoday.com/articles/71276.php [Accessed 2010 Jan 14]
Schering-Plough. Efficacy and safety study of the combined oral contraceptive NOMAC-E2 compared to a COC containing DRSP/EE (292002) [COMPLETED] (P05722) [ClinicalTrials.gov identifier NCT00413062]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Feb 5]
Schering-Plough. Effects on ovarian function of the combined oral contraceptive NOMAC-E2 compared to a COC containing DRSP/EE (292003) [COMPLETED] (P05723) [ClinicalTrials.gov identifier NCT00511433]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Feb 5]
Acknowledgements
Funding for the preparation of this manuscript was provided by Theramex Italy. Medical writing assistance for the preparation of this manuscript was provided by Ray Hill of inScience Communications. The author has declared that he has no conflicts of interest that are directly related to the contents of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lello, S. Nomegestrol Acetate. Drugs 70, 541–559 (2010). https://doi.org/10.2165/11532130-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11532130-000000000-00000